Cyclocreatine phosphateAlternative Names: cyclocreatine-phosphate-Amira
Latest Information Update: 20 Sep 2006
At a glance
- Originator Amira
- Mechanism of Action Creatine kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 12 Mar 1999 New profile
- 12 Mar 1999 Preclinical development for Cancer in USA (Unknown route)